The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Teacher spread

0.305 · how far apart the two teachers sit on this one work

Validation status

score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

BACKGROUND: Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments. METHODS: Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 100 000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates. FINDINGS: In 2017, there were 448 000 (95% UI 439 000-456 000) incident cases of pancreatic cancer globally, of which 232 000 (210 000-221 000; 51·9%) were in males. The age-standardised incidence rate was 5·0 (4·9-5·1) per 100 000 person-years in 1990 and increased to 5·7 (5·6-5·8) per 100 000 person-years in 2017. There was a 2·3 times increase in number of deaths for both sexes from 196 000 (193 000-200 000) in 1990 to 441 000 (433 000-449 000) in 2017. There was a 2·1 times increase in DALYs due to pancreatic cancer, increasing from 4·4 million (4·3-4·5) in 1990 to 9·1 million (8·9-9·3) in 2017. The age-standardised death rate of pancreatic cancer was highest in the high-income super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were observed in Greenland (17·4 [15·8-19·0] per 100 000 person-years) and Uruguay (12·1 [10·9-13·5] per 100 000 person-years). These countries also had the highest age-standardised death rates in 1990. Bangladesh (1·9 [1·5-2·3] per 100 000 person-years) had the lowest rate in 2017, and São Tomé and Príncipe (1·3 [1·1-1·5] per 100 000 person-years) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65-69 years for males and at 75-79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily attributable to smoking (21·1% [18·8-23·7]), high fasting plasma glucose (8·9% [2·1-19·4]), and high body-mass index (6·2% [2·5-11·4]) in 2017. INTERPRETATION: Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early detection and more effective treatment strategies for pancreatic cancer are needed. FUNDING: Bill & Melinda Gates Foundation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue

˜The œLancet. Gastroenterology & hepatology

Topic

Pancreatic and Hepatic Oncology Research

Field

Medicine

Canadian institutions

—

Funders

Đại học Quốc gia Hà NộiApplied Molecular Biosciences UnitI.M. Sechenov First Moscow State Medical UniversityUniversity of GondarUniversity of TabrizUniversidade do PortoBaki Dövlət UniversitetiBabol University of Medical SciencesBaqiyatallah University of Medical SciencesNational Center of Neurology and PsychiatryIslamic Azad UniversityUniversitetet i BergenLaboratório Associado para a Química VerdeGolestan University of Medical SciencesSeoul National University HospitalSeoul National UniversityUniversity of TorontoBauman Moscow State Technical UniversityFundação para a Ciência e a TecnologiaBill and Melinda Gates FoundationTabriz University of Medical SciencesPublic Health AgencyMansoura UniversityPublic Health Agency of CanadaMcGill UniversityFuel Cell Technologies ProgramSharif University of TechnologyDuke Global Health Institute, Duke UniversityTrường Đại học Duy TânIran University of Medical SciencesWuhan UniversityInstituto de Salud Carlos IIIMinistério da Ciência, Tecnologia e Ensino SuperiorRede de Química e TecnologiaGeneralitat ValencianaUniversity of WashingtonUniversità di Catania

Keywords

MedicinePancreatic cancerIncidence (geometry)DemographyCancerEnvironmental healthDisease burdenCancer registryMortality rateBurden of diseaseDiseaseBody mass indexGerontologyInternal medicinePopulation

Has abstract in OpenAlex

yes

API

/api/v1/works/W4233651632